Bone morphogenetic protein 2
As of the edition of 20 October 2026, Bone morphogenetic protein 2 is a protein: went quiet in 2019; acts on ACVR1, ACVR2A and ACVR2B and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Protein
- Registered trials
- 2, 0 stopped early
- Disease areas
- Bones, joints and muscles; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 2 |